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Histological coherent Raman imaging: a prognostic review
Marcus T. Ciceronea∗ and Charles H. Camp, Jr.a
Histopathology plays a central role in diagnosis of many diseases including solid cancers. Efforts are underway to transform this
subjective art form to an objective and quantitative science. Coherent Raman imaging (CRI), a label-free imaging modality with sub-
cellular spatial resolution and molecule-specific contrast possesses characteristics which could support the qualitative-to-quantitative
transition of histopathology. In this work we briefly survey major themes related to modernization of histopathology, review applications
of CRI to histopathology and, finally, discuss potential roles for CRI in the transformation of histopathology that is already underway.
1 Introduction
Histopathology has its roots in sixteenth century biology,1 and
currently plays a key role in diagnosis of many cancers and other
diseases. Nowadays, disease assignments from histology are gen-
erally based on the spatial arrangement of cell and tissue fea-
tures that are highlighted using stains and sample preparation
methods that were developed near the beginning of the 20th cen-
tury.2 The current standard is subjective, consensus-based tissue
analysis. This practice has held for many decades, however, it is
known to suffer from several important sources of variability,3–7
including differences in staining protocols and tissue analysis ap-
proaches among individuals and institutions. Further, while there
are general agreements regarding sets of features that indicate a
particular diagnosis,8 knowledge of and proficiency in identify-
ing these varies significantly with level and emphasis of training
among pathologists. Together, these factors lead to some degree
of diagnostic imprecision. Given the central role of histology in
influencing diagnosis and subsequent treatment regimens, and it
is not surprising that efforts are underway to increase objectivity,
repeatability, and precision of histopathological analysis.
Over the past several decades, a number of approaches have
been pursued to increase the amount of quantitative information
extracted from histology samples, and thus support improved an-
alytical performance of histopathology approaches. Immunohis-
tochemistry9 (IHC), introduced in the early 1940s, enhances im-
age information content through antibody-based contrast agents
for diagnostically valuable targets, such as cell surface markers
and structural proteins. This approach can yield information
on the spatial distribution of these diagnostic targets and has
proven very useful in some cases,10 but also has important limi-
tations.11–13 Other efforts have focused on quantifying image in-
formation and presenting it to physicians in the form of computer
aided diagnostic (CAD) tools. A requirement for widespread use
of CAD methods is that clinical tissue images be digitized. Al-
though histopathology analysis is generally performed directly
through the microscope, with no digital image ever acquired, dig-
ital recording of whole slide images (WSI) is becoming increas-
ingly common, particularly for training purposes.14
Vibrational spectroscopies such as Raman scattering and in-
frared absorption (IR) offer significant potential to increase the
information content of histology images. Like IHC, these modali-
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ties provide chemically specific and diagnostically relevant infor-
mation, but without the need of labeling. IR spectroscopy was
applied as early as 1952 for qualitative characterization of nor-
mal and neoplastic tissue.15 Several IR and Raman histopatho-
logical studies in the 1990’s through the 2000’s utilized multi-
variate analysis methods to provide probabilities of disease within
regions of interest.16,17 Some studies also provided relative abun-
dances of major tissue components having diagnostic value.18
While studies such as these showed impressive sensitivity and
specificity, they often did not provide image information that
could be easily integrated into a diagnostic decision. IR imag-
ing was not of sufficient spatial resolution, and Raman spectral
acquisition is sufficiently slow as to preclude imaging without sig-
nificant under sampling. These have been important limitations
for a field where image interpretation is central.
The recent advent of coherent Raman microscopies19 have fa-
cilitated rapid label-free imaging, and bright infrared (IR) sources
now available allow for IR imaging with higher spatial resolu-
tion.20,21 When spatially resolved, vibrational spectroscopy can
provide familiar and diagnostically important information such as
cell arrangement, phenotype, cellular and subcellular morpholo-
gies, structural proteins, and intracellular lipids. Because they
require little or no sample preparation, these modalities can pro-
vide this data with minimized latency between excision and avail-
ability of actionable information. Further, the intrinsically digi-
tal image format and potential for rich chemical contrast makes
vibrational histopathology a strong candidate for application of
CAD.
Here we review the application of coherent Raman methods to
histopathology, and look ahead through the lens of their potential
for meeting the needs of histopathology. In order to better evalu-
ate this potential, we first provide brief overviews of histopathol-
ogy workflow, diagnostic criteria & uncertainty, and technology-
related efforts underway to improve histopathology, including ap-
plication of infrared and spontaneous Raman spectroscopy.
2 Histopathology
2.1 Histopathology Workflow - A Brief Outline
Histopathology, the microscopic analysis of tissues for the pur-
pose of identifying disease, may be performed on tissue sam-
ples pre-operatively, intra-operatively, or post-operatively. Pre-
operative analysis is performed to help establish a detailed diag-
nosis and treatment regimen. Intra-operative and post-operative
histopathology is performed to ensure complete resection of dis-
eased tissue by confirming absence of disease in margins of ex-
tracted or in situ tissue. In cases where the benefit outweighs
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the risk, it is common practice to remove grossly healthy tissue
surrounding the tumor to decrease the likelihood of positive mar-
gins. When excising a margin of nominally healthy tissue is con-
traindicated, such as for brain, the surgeon takes care not to re-
move more tissue than is justified. In such cases, intra-operative
histopathology studies are sometimes performed on flash-frozen
resected tissue to ensure that the entire tumor has been removed.
The tissues are analyzed immediately, but an intra-operative his-
tology analysis typically takes 20 to 30 minutes, and so prolongs
the surgery.
Pre- and post-operative histopathology studies are typically
done in a batch mode, and usually take a day or two to wend
their way through the process, requiring approximately 13 hours
of actual processing time. In this process, excised tissue is first
grossly examined (by eye) for diagnostic information, and pre-
pared for microscopy. Tissue samples are typically fixed and em-
bedded within paraffin wax, and some of the tissue is sliced in 10
to 50 νm thick sections. These formalin-fixed paraffin-embedded
(FFPE) sections are then stained (typically with hematoxylin and
eosin [H&E]) and mounted for inspection. In a large hospital, a
pathologist may inspect 500 histology slides in a day. Diseased
regions are frequently small, so the clinician may spend a signif-
icant amount of time combing through normal tissue. In order
to search more efficiently, pathologists will often identify land-
mark species such as blood cells and vessels, lymphocytes and
ducts, which are frequently found in vicinity of cancerous lesions.
Preliminary microscopic analysis and diagnosis are often carried
out by a single pathologist. In difficult cases, a panel of experts
may review slides from a case, and additional staining may be
requested to identify diagnostically important species that H&E
staining does not highlight. Ultimately, analysis and diagnosis are
generally reviewed and signed-out by an attending physician.
2.2 Diagnostic Criteria
The primary diagnostic criteria for most cancer types are related
to intercellular organization.8 There are a number of additional
criteria that are specific for various cancer types. These include
cellular features such as number density of mitotic events, in-
filtration of immune cells, degree of cell differentiation within
and surrounding the tumor, the degree of necrosis, abnormal nu-
clear shape or intracellular lipid levels, the appearance of over-
developed mitochondria, and chromatin clumping.8,22–24 Tissue
structural features are also important for some cancer types, such
as prostatic adenocarcinoma.25 These features may include aci-
nar organization, mineralized tissue, mucin or polysaccharide de-
posits, the presence or absence of structural proteins, such as
laminin, elastin, or collagen. In the course of qualitative tissue
classification, the pathologist must evaluate whether observed
features fall in or out of the normal range. These judgments are
subjective and thus susceptible to variability which is in a sense
uncontrolled, because it cannot be quantified on a case-by-case
basis.
2.3 Diagnostic Uncertainty
While it is not currently feasible to assign diagnostic probabilities
on a case-by-case basis, most studies address the issue of diagnos-
tic uncertainty through analyzing outcomes in groups of patients.
These studies can be classified into several types, and, while the
results of these studies vary significantly, a few general trends
emerge.
One type of study involves mandatory or voluntary review of
a wide range of tissues by "peer" physicians (i.e., not necessarily
subspecialty experts). In this class, Kronz et al.26 and Raab et
al.27 report on inter-institution or institution-wide studies where
large numbers of cases (6171 and 6162 respectively) covering
many tumor types were reviewed. Kronz et al. found 1.5% dis-
cordant diagnosis resulting in a major modification in therapy or
prognosis was observed.26 The majority of these cases involved
a change between benign and malignant or a major change in
tumor classification, and changes involving only a modification
of tumor grade or stage were not included. That study found
significant variability in diagnostic discordance with type of tis-
sue. Serosal surfaces and the female reproductive tract tissues
had 9.5% and 5.1% diagnostic discordance respectively, the high-
est found in the study. Raab et al27 estimated an error rate 6.7%
from self-reported discrepancies upon second review at 72 insti-
tutions. In that study, only 1.1% of discordant diagnosis resulted
in a major modification in therapy or prognosis.
Addressing these types of studies, Ho et al.28 argue that statis-
tics based on second review likely reflect an underrepresentation
of errors since the reviewer often has knowledge of the original
diagnosis and the sign-out pathologist. They argue that such a
priori knowledge has led to biased review in similar situations.29
In another class of study, previously diagnosed cases for a sin-
gle tissue type are analyzed by a panel of sub-specialists. Higher
discordant diagnosis rates are typically found in these types of
studies. Lurkin et al.30 report on a review of all sarcoma cases
(366) in the Rhone-Alpes region of France over a 12 month pe-
riod. They found that 19% of cases resulted in change of type
or invalidation of diagnosis, and 27% of cases resulted in change
of grade or subtype of diagnosed cancer. Bruner et al.31 found
similar results for 500 neuropathology cases submitted to a spe-
cialist review committee. They found that 9% of reviews resulted
in immediate significance for therapy or intervention, and 19%
resulted in a change in type or grade of glioma. Similarly, spe-
cialist review of 602 prostate adenocarcinoma cases32 led to a
change in the Gleason score by at least 1 point in 44% of cases,
and patients’ risk category was increased in 11% of cases. Like-
wise, of 340 patients presenting for second opinions regarding
breast cancer, 80% resulted in some diagnostic change, with 8%
of reviews leading altered surgical therapy.33 In another study,
131 bladder carcinoma cases underwent secondary review, with
18% exhibiting significant discrepancies.34 In a gynecological on-
cology35 study of 295 referred patients, 5%, resulted in diagnos-
tic changes that had major therapeutic or prognostic implications.
Arriving at definitive numbers for diagnostic uncertainty is out-
side the scope of this review. However, it does seem clear from
the studies cited above that the uncertainty is significant for some
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cancer types. This widely recognized fact was reflected in a re-
cent survey of pathologists,36 which showed that physicians on
average expect 10% diagnostic uncertainty from histopathology
for cancer, and that lack of sub-specialty expertise is seen as the
most important factor contributing to misdiagnoses. Based on
these facts, one may be inclined to favor the sub-specialist review
literature, and the slightly higher discordant diagnosis numbers
found therein. The overall picture is that difficulty in diagnosis
varies significantly with tissue and tumor type, and many human
factors figure in precision and accuracy of diagnostics.37 36
2.4 Impact of Diagnostic Uncertainty
Table 1 shows published figures for cancer rates, inter-observer
diagnostic variability among pathologists, and cost associated
with initial treatment. It appears that approximately 200,000
people each year in the U.S. are either incorrectly informed that
they have cancer, and subsequently undergo invasive treatments,
or are incorrectly told that they do not have cancer, and miss the
opportunity for potentially life-saving treatments. One might as-
sume that half of misdiagnosed cases are false positive and half
are false negative. Under this naive assumption, one estimates
the cost of unnecessary procedures is $2.5 B annually in the U.S.
Of course, the cost of missed treatment is harder to estimate, but
misdiagnoses are uniformly the largest reason for medical law-
suits, which cost $55.6 B annually, or 2.4% of all health spend-
ing.38
The magnitude and gravity of this problem is not lost on physi-
cians and technologists, and the field of histopathology has been
slowly evolving to provide better informed and precise diagnoses.
Several innovations have been in process of adoption over the
past decades.
2.5 Immunohistochemistry
Immunohistochemistry (IHC), first introduced in the 1940s, typ-
ically uses fluorescently tagged antibodies to provide image con-
trast specific to proteins of diagnostic value. Most IHC tags are
targeted to functional proteins, such as cell surface markers;45
however, soluble46 and structural8,47–49 proteins are also tar-
geted. The IHC approach facilitates mechanism-linked disease de-
tection, and has enjoyed some important successes. For example,
a protein (KIT), found to be mechanistically related to gastroin-
testinal stromal tumors (GISTs), is easily visualized through IHC
labeling, and has found widespread use in diagnosing GISTs.10
While it now seems that KIT labeling is also prone to false posi-
tives in some cases,12 the use of IHC for KIT detection has never-
theless simplified detection of GISTs, which was notoriously con-
troversial with regard to classification, line(s) of differentiation,
and prognostication.10 In spite of successes, IHC in general has
some drawbacks including variability of labeling,11 and incom-
patibility with some stains. Compatibility issues include back-
ground fluorescence from a stain, interfering with IHC detection,
and stains chemically modifying the affinity antibodies used in
IHC. H&E has both of these issues. Additionally, while IHC im-
ages can provide specific chemo-spatial information, they are also
interpreted subjectively which can lead to variability in diagnostic
Fig. 1 WSI image of prostate adenocarcinoma tissue from set of
Genitourinary Block training in the preclinical curriculum at the
University of Arizona College of Medicine, in Tucson, AZ. 14
outcomes.13
Improved diagnostic precision has been achieved by multiplex-
ing classical and IHC stains, where the various contrast agents
are imaged together.50 Alternatively, cyclic IHC labeling24,51–53
of samples facilitates registered imaging of many proteins. Such
approaches can lead to improved specificity for cancer character-
ization, but can add considerable complexity and, in the case of
serial IHC, require up to a day for each labeling cycle.53
2.6 Whole slide imaging
Pathology slides are typically viewed and analyzed directly
through a light microscope for diagnostic purposes. Image dig-
itization is not a common practice for histopathology, but that is
now beginning to change. Whole-slide imaging54 (WSI), which
entails digitization and storage of entire tissue slides, was intro-
duced in the mid 1990s. Image acquisition speeds were initially
too slow to be of practical use, but current WSI instruments have
pixel acquisition rates on the order of 3 MHz, allowing them to
generate bright-field images of a 1 cm2 tissue sample at 500 nm
resolution in about 2 minutes; roughly the time a pathologist
might spend on a tissue sample of similar size. WSI is now used
widely in teaching environments,14 and has been fully adopted in
some hospital systems.55 WSI is also useful for quality assurance,
consultation, and telemedicine applications.28,55
Figure 1 shows an example of a prostate adenocarcinoma dis-
play from a pedagogical WSI application, allowing simultaneous
view of an image thumbnail, and a detailed sub-image section.14
This sort of data presentation has obvious pedagogical and prac-
tical benefits, but large, high-resolution images such as this may
occupy ≈1 Gb of disk space. Thus, the work of a single pathol-
ogist may occupy 0.5 Tb / day, and storage space requirements
are often cited as a potential barrier to widespread acceptance
of WSI.56 Another barrier is slightly reduced image quality com-
pared to direct microscopic observation.55 There are further con-
cerns about variation in sample preparation and staining prac-
tices, and that image capture and coloration can vary over an
important range among WSI instruments. Consideration of these
issues is currently underway at the U.S. Food and Drug Adminis-
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Table 1 Major cancer types and diagnostic uncertainty
Type New
Cases 39
Diagnostic
Uncertainty
Initial
Cost 40
Unnecessary
Treatment Cost†
Raman
Uncertainty
Breast 250 k 20% 7 $23 k $575 M 5% 18
Lung 225 k 10% 3 $61 k $680 M 10% 41
Prostate 180 k 30% 5 $20 k $540 M 5% 42
Colon & Rectal 135 k 10% 6 $52 k $350 M 5% 42
Bladder 77 k 40% 4 $21 k $320 M 7% 43
Melanoma 76 k 25% 44 $5.5 k $52 M 5% 44
†These values are estimates assuming diagnostic uncertainty is evenly distributed between precision and accuracy.
tration.57
2.7 Computer Aided Diagnosis (CAD)
CAD approaches support improved diagnostic precision by pro-
viding image-derived, diagnostically relevant information to
pathologist. Efforts towards CAD began in the late 1990s with
detection of malignant masses in radiological images of breast
tissue,58 and CAD is now routinely used in radiology for iden-
tification of lesions. Further, it seems that the prevalence and
sophistication of CAD is likely to grow. In 2015, IBM acquired
Merge Healthcare, for its 30 billion radiological and histological
images, with the intent of using the image data to train Watson,
their physician assistant software.59
While radiological CAD is now well-integrated into the diagnos-
tic process, histological CAD is not used routinely. This dichotomy
may be due in part to the fact that the former simply provides ev-
idence for the presence of tumors, while the latter must address
the more complex questions of tumor type and grade, and deals
with images of higher complexity. Numerous algorithms have
been proposed for diagnosis of specific cancers,60–62 but there
has not been significant clinical adoption. Histological CAD, how-
ever, is beginning to emerge from the research-only phase, as a
number of companies are becoming involved in developing these
tools.63
Histological CAD systems may exploit a large range of image
features to derive clinically significant information,60 including
object size and shape, intensity, color, texture, and inter-object
organization. Approaches for extracting these inputs from im-
ages have been reviewed recently.64,65 The image processing as-
sociate with CAD will generally include some or all of the fol-
lowing steps: 1) Preprocessing, such as color and intensity nor-
malization and de-noising. 2) Feature identification using thresh-
olding or segmentation approaches. 3) Quantification of relevant
feature characteristics, such as shape, size, spatial arrangement,
texture, or color. 4) Reduction of data dimensionality using meth-
ods such as principle component analysis. 5) Classification based
on the reduced-dimension dataset. Steps 2 through 5 (and some-
times step 1) are collectively referred to as "machine learning".
We briefly discuss these steps below.
2.7.1 Preprocessing
Image analysis and quantification ultimately depend on spatial
variation in color and intensity. It is therefore crucial that varia-
tions in tissue properties of interest give rise to the same range of
image color and intensity variations within a sample, or between
samples. However, in practice, it is often difficult to achieve suf-
ficient image uniformity. Many factors such as inconsistency in
staining or storage conditions, illumination brightness and uni-
formity or sample tilt can induce significant variation in response
of the captured image to actual changes in tissue properties.
Use of blank images66 or reference materials can reduce inter-
image variability, but this is often insufficient. In order to min-
imize these variations, preprocessing steps such as color and in-
tensity normalization are often employed. Color convolution67
quantifies staining densities of a small number of contrast agents
based on the fact that light absorptivity of individual stains is lin-
ear in log space. This approach continues to be developed, and
can be used to map image color and intensities from many sam-
ples onto common range,68 assuming each image contains sim-
ilar ranges of features. However, color and intensity normaliza-
tion approaches can lead to significant artifacts when based on
assumptions that the proportion of pixels or range of stain in-
tensities from each image in a set should be identical.69 In cases
where a given stain vector may not be appropriate for all samples,
individual vectors can also be normalized to a single image.69
2.7.2 Image Segmentation
Segmentation is the process of grouping like pixels into super-
pixels, and generating boundaries around regions or objects with
similar properties in the image. There are many segmentation ap-
proaches. The simplest of these is thresholding, where pixels in
an image are converted to 0 or 1 depending on whether they meet
a threshold criterion. The threshold may be set by consideration
of pixel values in the overall image70 or of local regions if the im-
age is expected to have trivial nonuniformities.71 Watershed72 is
another common segmentation approach where the boundaries
of enclosed object shapes are defined by local maxima in pixel
values. K-means clustering is another approach which finds, for
some number (k) of clusters, the cluster location and boundaries
that minimize a merit function, designed, for example, to group
pixels of similar intensity. Fuzzy clustering73 and Gaussian mix-
ture models? allow for the possibility of overlapping objects, as-
signing each pixel to one or more contiguous objects that are de-
fined in such a way to minimize variation of a particular property
within the boundaries of the object. The optimal configurations
of these clusters are often found using expectation maximization
approaches.74
Another approach uses active contours, which are deformable
splines that encompass image segments. They are constructed to
minimize some energy function that may have contributions dic-
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tating the stiffness of the spline, the placement of the spline on
the image (e.g., lowest energy at a minimum image gradient lo-
cation), and a term that encapsulates a priori knowledge of image
segment shape or location.65 These splines can be parameterized
(SNAKES)75 or unparameterized (level set methods).76 Each ap-
proach has strengths and weaknesses, with SNAKES being more
robust to noise, and level set methods having greater flexibility
to accommodate variable topology. In cases where salient aspects
of the image segment shape is known, Bayesian analysis of tem-
plate comparison77 has been successful, and found robust to im-
age variation. Each of these segmenting approaches may have
trouble with overlapping features of interest, and active contours
are prone to inclusion of unwanted background objects.64 Also,
Bayesian methods are, in general, computationally expensive.
Of course, pixel-level and active contour approaches are not
mutually exclusive. It is possible to leverage the strengths of each
in a single algorithmic approach.78
2.7.3 Feature Selection
Image segmentation prepares one to select features that may be
used for quantification or in predictive model construction. This
step frequently reduces complexity of the data to be considered
and may be performed with or without user supervision. Super-
vised methods require the user to specify properties of features to
be found, whereas unsupervised methods discover these proper-
ties autonomously from the data. The latter class includes prin-
ciple component analysis (PCA),79 which finds a minimum set of
orthogonal, linear combinations of the original data dimensions
that retain the majority of signal variation. Exploratory factor
analysis (EFA)80 is a similar approach, but differs in that it allows
for a component of random error in apparent associations be-
tween features and observed variables. Independent component
analysis (ICA)81 is also similar to PCA, except that ICA attempts
to unmix signals by using the non-Gaussian character of individ-
ual signal elements to separate them into components that are as
statistically independent from one another as possible.
Linear discriminant analysis (LDA) is a commonly used super-
vised feature selection approach that assumes independent vari-
ables are normally distributed. It is similar to PCA, except that
the feature types are specified by the user. A comparison of PCA
and LDA can be found in Martinez et al.,82 who prefer PCA when
the training data set is small, other factors being equal.
Similar to methods mentioned above, manifold learning (ML)
approaches project an M dimensional data set to N dimensions,
where, N < M, and preferably, NM. Both supervised and unsu-
pervised ML approaches exist, and these differ from those above
in that there is no assumption of linearity in the relationship be-
tween the features of interest and the original data.64
2.7.4 Feature Quantification
Once diagnostically important image features are identified, their
properties may be quantified. Spatial arrangement of cells is al-
most always important, and the Feldman group77,83 provide an
example of how this can be characterized. They start with Voroni
tesselation, in which the image is partitioned into convex poly-
gons such that each polygon contains exactly one nucleus and
all points within the polygon are closer to the center of their nu-
cleus than to that of any other. From this starting point, they use
Delaunay triangulation to draw lines between nuclei that shared
a Voroni boundary, and then choose a set of lines that form a
continuous structure of minimum lenght - a minimum spanning
tree. From characterization of the tree and a dozen other simi-
lar metrics, were able to discriminate Gleason 3, 4, and normal
regions for prostate,83 and evaluate Bloom-Richards criteria for
breast cancer.77 Automated analysis and classification compared
favorably to a manual approach, yielding better results in every
categorization except cancer vs non-cancer in breast tissue.
2.7.5 Classification
Once image features have been quantified, the associated metrics
may be used to classify tissues regarding their disease state. One
approach is to use decision trees, which are a series of questions,
the answers to which lead directly to a classification. These ap-
proaches have a number of attractions; they are similar to the
approach a human might use to classify a tissue and are transpar-
ent. Another is that they have low systematic bias.84 A potential
drawback is that they tend to have high variance, but this can
be reduced using approaches such as random forests,84,85 where
many decision trees (the forest) are grown on varying subsets of
the data, and decision nodes of the final tree are based on statis-
tical sampling of the nodes in the forest.
Deep learning is another route to classification. These ap-
proaches are an evolution of neural networks in which the data
vectors are iteratively transformed using nonlinear functions in
such a way as to emphasize image aspects having predictive
power. Using these approaches, segmentation, feature selection,
and classification are all done at once, and all without user inter-
vention. However, the entire process is opaque to the user in that
there is no way to know what features the model is using for clas-
sification. Thus, there is thus no way to know when the model is
likely to fail. In fact, only to the extent that the data set on which
the deep learning model was trained is comprehensive, can the
characterization be reliable. By way of apparent counterexample,
however, Cirean et al. were able to use a relatively small sampling
of mitotic events to create a highly effective deep learning model
for detecting mitoses in H&E images.86 Nonetheless, building a
comprehensive data set for deep-learning image recognition is ap-
parently the intent of IBM in acquiring a company with access to
30 billion radiological and histology images.59
2.7.6 Roles for CAD in Histopathology
CAD assists the pathologist in one or more of the image analysis
steps leading to diagnosis. The assistance could range from sim-
ply providing quantitative image metrics, to contextual reminders
of disease mimics to apparent probabilities of various diagnoses.
Even the most basic level of CAD assistance - that of provid-
ing image feature identification, such as of nuclei or regions of
potential metastases85 may be quite valuable. In many cases, a
pathologist may search for regions of interest (ROIs) that cover
only a small fraction of the sample. Identifying such regions up
front, or even identifying landmark species that typically signify
such regions could provide a significant time savings.53
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Feature quantification might be considered the next level of
sophistication where CAD approaches could be of high value.
We find evidence for this by considering the work of Fuchs and
Buhmann,87 who found 10% disagreement on location and size
of nuclei in a renal cell carcinoma sample between two sub-
specialists, and inter- and intrareader disagreement of 42% and
21% respectively for counts of normal and atypical nuclei among
five pathologists who were not sub-specialists. This level of vari-
ability is comparable to the overall diagnostic uncertainty dis-
cussed in Section 2.3, and suggests that correct identification of
relevant features may play a significant role in diagnostic uncer-
tainty for this and other cancers. Image analysis approaches dis-
cussed in the previous sections can provide quantitative charac-
terization of key features, such as cell density61 or mitotic event
counts86 and nuclear shape metrics77,83 at precision levels sim-
ilar to that of sub-specialist analysis in the Fuchs and Buhmann
work.87
While CAD work is largely done using H&E,86 improved ap-
proaches to image contrast would likely lead to increased relia-
bility of CAD outputs.63 Naturally, an expanded contrast pallet
serves to put image-derived metrics on a more solid footing.53
Even the simplest pixel-level thresholding methods can be quite
reliable when pixel intensity values are related to specific chemi-
cal or functional information. For example, pixel-level analysis of
vibrational spectra resulted in accuracies of 94%-100% for clas-
sification of ten disparate histologic classes,88 98% for positive
prostate nuclei from IHC images with contrast for androgen re-
ceptor protein,89 and 95% for micro-metastasis from cytokeratin-
stained lymph node sections.90
3 Spectroscopic Histopathology
Vibrational spectroscopy is a rich source of enhanced spatio-
chemical information that has been applied to histopathology, al-
beit primarily in a research mode. From such studies it appears
that much of the information sought through staining, and per-
haps more, is available without labeling, from techniques such as
Raman or IR spectroscopy that can measure molecular vibrations
intrinsic to the species of interest in the specimen.
It is common to describe molecular vibrations in terms of oscil-
latory motions along vectors (Q), called "normal modes." These
modes constitute collective motion of molecular substituents that
preserves the overall symmetry of the molecule during motion.
The modes have discrete allowed states with energies approxi-
mately equal to (ν + 1/2)h¯ωm, where ν are integer values, and
hωm is the ground vibration frequency. The ground state vibra-
tional frequencies and energies vary depending on the strengths
of bonds and masses of atoms involved in the normal mode mo-
tion. Transitions with ∆ν = ±1 are most often measured, and
those with energies in the range (500 to 3100) cm−1 are typically
of interest in biological systems. Signatures in the higher energy
range, (2800 to 3100) cm−1 arise from transitions between states
of modes involving symmetric or asymmetric stretching of C-H
bonds. The range (1800 to 2800) cm−1 is referred to as the qui-
escent region because transitions of natural biological molecules
typically do not appear in this range. The greatest variety of vibra-
tional transitions in biological molecules occur in the fingerprint
a b
c d
Fig. 2 a: IR spectra of major cell components. 91 b: Raman spectra of
major cell components. 91 c: IR fingerprint spectrum of whole cells 92. d:
Raman fingerprint spectrum of whole cells 93
range (500 to 1800) cm−1.
Transitions between these states are usually detected through
absorption, emission, or inelastic scattering of light. The prob-
ability for photon absorption or emission is significant when
∂µ/∂Q 6= 0, where µ is a mode’s permanent dipole moment. By
contrast, inelastic scattering is important when ∂α/∂Q 6= 0, where
α is the molecular polarizability. Infrared and Raman spectro-
scopies are respectively based on absorption and inelastic scatter-
ing, and are often complimentary since many modes for which
∂µ/∂Q= 0 will have ∂α/∂Q 6= 0, and vice versa.
Figure 2, panels a and b show IR and Raman spectra for major
classes of tissue constituents. Since these have distinct signatures
in both spectroscopies, they can be identified by either method.
On the other hand, IR absorption lines are slightly broader. This is
of consequence in the fingerprint region, where spectral lines are
quite congested. Panels c and d of Fig 2 show fingerprint regions
of IR and Raman spectra from cells, illustrating that the width of
the individual IR peaks makes it difficult to separate them into
more than just a few distinct contributions without peak fitting.
On the other hand, Raman spectra from similar systems contain a
large number of easily resolvable peaks, providing a much higher
level of chemical specificity. The differences can be quantified in
terms of information content, or entropy, Si = ln(Ωi), where Ωi
is the maximum number of distinct spectral states one can dis-
criminate. Here, Ωi = SNRM where M is the number of spectral
peaks and SNR is the signal to noise ratio in each peak. We can
estimate this value by noting approximately 15 peaks in the IR
spectrum, 5 peaks in the Raman CH region, and 45 peaks in the
Raman fingerprint region. Assuming SNR=15 for IR peaks and
for CH stretch Raman peaks, and SNR=3 for Raman fingerprint,
we obtain Ωi = 1017, 106, and 1021 for IR, Raman CH, and Ra-
man fingerprint spectra respectively (1027 for the entire Raman
spectrum). Partly for this reason, Raman is found to have better
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specificity for classifying cancer.94
Given their capacity for encoding chemical information, it
is not surprising that these spectroscopies have been applied
to many general aspects of disease diagnoses.95,96 They have
also been used for guidance in tissue sampling,97 augmented
bases for stratified diagnosis,98 and intraoperative guidance dur-
ing tissue-conserving resection.99,100 Of particular present in-
terest is the considerable body of literature showing that vi-
brational spectroscopy provides diagnostically significant infor-
mation for cancer diagnosis in conjunction with histopathology.
There have been many excellent reviews on this topic in recent
years,91,95,101–105 so here we will only summarize relevant as-
pects.
Histology-related studies using vibrational spectroscopy began
to appear in the 1960s106 for IR, and in the 1980s for Raman,107
and to date, there have been thousands of publications. How-
ever, it appears that only in the past decade or so that IR and
Raman technology have been sufficiently developed to produce
meaningful studies.91 Recent work provides rather convincing ev-
idence that vibrational spectroscopy can detect diagnostically im-
portant changes in tissues, routinely yielding objective sensitivity
and specificity figures generally in the 85% to 95% range for de-
tection and classification of cancers, even when spectra on which
discrimination is based are usually taken at just a few spots from
normal and diseased portions of tissue.
In one example, Pence et al.104 discuss 26 large studies of ep-
ithelial cancers (> 50 patients), among which, the average sen-
sitivity and specificity obtained using Raman spectroscopy were
89± 7% and 88± 8% respectively. Such precision generally ex-
ceeds that possible by subjective morphological analysis. Similar
examples are listed in the final column of Table 1, indicating a
reduction in diagnostic uncertainty by more than a factor of two
in most cases. Table 1 also provides prevalence, histology-based
diagnostic uncertainty and initial treatment costs for the six most
common cancers in the US. Assuming naively that diagnostic un-
certainty is evenly distributed between precision and accuracy, we
estimate that using Raman spectroscopy to supplement histology
could save >$2B/ yr in unneeded treatments, and reduce the bur-
den on patients and families associated with missed opportunities
for earlier treatment.
3.1 Vibrationally Detected Cancer Markers
The impressive diagnostic value of vibrational spectroscopy ac-
crues from its inherent chemical specificity. It can reveal infor-
mation that is otherwise available only by methods such as IHC,
polymerase chain reaction or gene arrays,91 leading to more pre-
cise tissue segmentation,88 and providing new prognostic infor-
mation.117
Table 2 gives a partial list of cancer biomarkers that have been
used in Raman studies to classify neoplastic and cancerous tis-
sues, and lists spectral peaks used to identify those markers. Most
markers have several peaks, facilitating increased robustness in
detection, to the extent that noise in separate peaks is uncorre-
lated, but even correlated noise can be suppressed if peak ratios
can be used. The fact that most of the peaks used in these Raman
studies are found in the fingerprint region is due to the high spec-
tral density and low peak widths found there, and underscores
the importance of this spectral range for chemical specificity.
Many of the markers listed in Table 2 are commonly visual-
ized in pathology through IHC or classical stains, but, of course
those methods require labeling. Not only is vibrational contrast
label-free, it can also be semi-quantitative when peak amplitude
ratios are used. Accordingly, peak pairs that provide information
on protein-to-DNA or protein-to-lipid ratios, or on degree of un-
saturation in fatty acids frequently yield highly reliable metrics of
disease type and grade.41,108,116,118–121
Macromolecular structure and material phase information are
also available from vibrational spectroscopy, and can be useful
in cancer detection and diagnosis. For example, degree of cal-
cification is a known marker for many cancers.8 Using classical
stains, it is difficult to distinguish between types of calcification,
but such discrimination turns out to be important. Haka et al.18
showed that Raman spectroscopy can be used to easily distinguish
CaC2O4 from Ca5(PO4)3, and that their relative abundances cor-
relate with malignancies in breast cancer. Raman spectroscopy
also contains structural and hydrogen bonding information for
lipid, protein, and nucleic acids, which has diagnostic value for
many cancers.18,44,110,112
Spectral changes between healthy and diseased tissue can be
striking,41,122 or subtle,91 but generally appear in the context of
highly complex spectra from the tissue. Thus, while it is some-
times possible to determine identity of diagnostically relevant
species though differences between spectra from normal and dis-
eased tissue,111 this is sometimes not possible even when the pri-
mary marker species is known.113 For this reason researchers of-
ten derive diagnostic information from tissue spectra using spec-
tral pattern recognition approaches.
3.1.1 Machine Learning on Spectral Features
Many of the machine learning methods used for image feature
selection (see Section 2.7.3) are also used for spectral feature
selection and classification. Unsupervised feature selection meth-
ods such as principle component analysis (PCA, linear transform),
singular value decomposition (SVD, linear transform), and ker-
nel PCA (KPCA, nonlinear transform) generate orthonormal basis
vectors containing correlated spectral features.123,124 These basis
functions may contain positive and negative spectral elements, so
their interpretation is not always clear. However, they are useful
for denoising or dimensionality reduction, in which only a subset
of basis vectors are retained and spectral information of interest
is reconstituted through linear combinations of the retained vec-
tors.125 Other unsupervised feature selection methods, such as
nonnegative matrix factorization124,126 (NMF; also ‘positive ma-
trix factorization’), positivity constrained multivariate curve res-
olution124,127–129 (MCR) and vertex component analysis123,130
(VCA), are designed to retrieve physically meaningful, positive-
valued spectra from which abundance maps can be directly gen-
erated. MCR and NMF techniques return components of spectra
that carry discriminating information, and may or may not return
realistic spectra of molecular constituents, depending on their im-
plementation. VCA assumes that there are ‘pure pixels’ for each
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Table 2 Major cancer markers detected through vibrational spectroscopy
Marker Relevant
Cancers
Spectral
Lines [cm−1]
Metabolic Markers
DNA (relative abundance) breast 18 larynx 108 668, 678, 728, 750, 785νO−P−O 825 νO−P−O 1093νPO−2 , 1336, 1488, 1580
lipid (structure and relative
abundance)
breast 18 colon 42,109 bladder 43
skin 44,110
1309τCH2 1445δCH2 1654νC−C 2850νCH2 ,sym 2880νCH2,asym 2920νCH3 ,sym
2960νCH3 ,asym
cholesterol ester breast 18 brain 111 430, 702, 1302, 1442, 1740νC−O
glycogen bladder 43 prostate 42 brain 111 472, 481, 846, 932
creatinine breast 112 600νN−CH3 678νC−O 685τC−S 692δCO2 840δN−CH2 903νC−C−N
Structural Molecules, etc.
protein structure skin 44 melanoma 44 1660νC−O (Amide I) 2850νCH2 ,sym 2880νCH2 ,asym 2920νCH3 ,sym 2960νCH3 ,asym
keratin epithelial cancers 113 623νCS, 643νCS, 850δCCHaromatic, 885ρCH2 933, 1002νC−C (ring breathing),
1031 (phenylalanine), 1200 1350 (Amide III) 1450τCH 1650νC−O (Amide I),
2940νCH3
collagen breast 18 prostate 42 colon 42
lung 41,114 skin 115
855, 938, 1004νC−C 1260νCN,δNH 1314ωCH3CH2 1445δCH2 1660νC−O 2940
elastin lung 41 1442δCH2 1660 νC−O
carotenoids bladder 43 lung 41 brain 111 1159, 1523
polysaccharides brain 116 856
Others
phospholipids lung 41 brain 111 719 1442δCH2
CaC2O4, Ca5(PO4)3 breast
18 brain 116 912νC−C 960νP−O 1477νC−O
phosphatidylcholine adenocarcenoma 91 719, 1666νC−O
trypotphan lung 41 prostate 42 650τC−C 1260νCN,δNH
proline prostate 42 939νC−C
tyrosine prostate 42 1176νC−H 1217νC−C6H5
ν-stretch, δ -scissoring, ρ-rocking, ω-wag, τ-twist
molecular entity (i.e., the unmixed spectrum of each pure chemi-
cal component is represented at least once among all the spectral
pixels). Methods that are explicitly designed to return spectra cor-
responding to real molecules are termed ‘endmember extraction’
or ‘spectral unmixing’.
These unsupervised feature extraction methods frequently
serve as the input to unsupervised and supervised classifica-
tion methods. Unsupervised methods, such as K-means cluster-
ing123,130 (KMC), divisive correlation cluster analysis (DCCA),
and agglomerative hierarchical cluster analysis (AHCA), link to-
gether related spectra based on spectral proximity metrics.123 Su-
pervised methods, such as linear discriminant analysis95 (LDA),
partial least squares131,132 (PLS), support vector machines133,134
(SVM), and random forest classifiers,130,135,136 rely on training
data to generate a classification model. These models may be
conservative or relaxed according to clinical need. For applica-
tions such as tissue-conserving resection,99 one may choose a
conservative model to minimize false positives. Alternatively, if
the aim is to reduce the burden on pathologists, one could design
a model that may include false positives, but automatically clas-
sifies the most clear-cut cases, leaving the rest for inspection.137
Training these models may be arduous, requiring many datasets
and extensive validation; but post-training classification may be
rapid.130,132 There are, additionally, ‘semi-supervised’, methods
that aim to incorporate known and unknown information into
classification problems, such as hybrid linear analysis138 (HLA)
semi-supervised PCA-linear discriminant analysis139 (PCA-LDA).
Deep learning140 (DL) and artificial neural networks141,142
(ANN) constitute an important family of methods that have re-
ceived significant attention recently. These methods rely on lay-
ers of interconnected decision units or ‘neurons’; typically 1-2
layers for ANN approaches, and potentially many layers for DL
approaches. Whether employed as supervised or unsupervised
learning, the weights and the interconnection strengths of the
neurons are iteratively modified to optimize a merit function.
One of the primary strengths of ANNs and DL is that nonlinear
and extremely complex interconnections can be created within
the network that may not be possible with traditional linear or
nonlinear methods such as those mentioned above. A significant
challenge to ANNs and DL, as with all supervised techniques, is
the requirement that the training set be comprehensive in that
it is representative of all future data. Another challenge is that
these approaches are ‘black box’ in that it is not currently clear
how to understand what data features are found to be important,
and how they are used in the evolved ANN/DL neural connection
architecture. Interpretation of ANNs and DL is an active area of
research.143
3.1.2 Spatio-Spectral Analysis
The diagnostically relevant information contained in vibrational
spectroscopy from tissue samples is useful for histology to the ex-
tent that it can be spatially resolved on relevant length scales .
Raman and IR spectroscopies are both conducive to spatially re-
solved acquisition, and both have been used in an imaging modal-
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ity with tissues.
Thanks to recent commercial availability of quantum cascade
lasers, approaches20 for IR imaging at spatial resolution as high
as 1µm are now feasible, making it possible to generate gross tis-
sue maps based on IR absorption. Since the chemical specificity
of IR spectroscopy is sufficient to easily discriminate among tissue
regions such as epithelium and stroma,144 and between benign
and malignant tissue,88 IR maps can be merged with H&E im-
ages to indicate tissue regions of interest,117 as shown schemati-
cally in Figure 3 a. Morphological features extracted directly from
such maps have been used to classify tissue samples as cancer or
non-cancer, with high accuracy.145 This automated ability could
provide considerable value, as mentioned in Section 2.7.6.
From a spatial resolution perspective, Raman imaging has an
important advantage over IR in that it uses visible or near infrared
wavelengths, so can reach spatial resolution 2 to 3X higher than
with IR, making cellular and sub-cellular imaging possible. The
combination of high resolution and rich fingerprint spectra allows
for significant information in addition to providing classification
of tissue regions. For example, Raman imaging can provide label-
free identification of cell type,146 distribution123,147 and content
of organelles.148 Important functional information is also avail-
able, such as DNA to protein ratio of nuclei,149 the cell cycle
state,147,150,151 and whether immune cells such as leukocytes are
activated.91,152 Examples of cellular function and organelle dis-
tribution maps generated with Raman spectroscopy are shown in
Fig.3 b and c.
Although IR and spontaneous Raman imaging can provide use-
ful diagnostic information, both have practical drawbacks. For
example, conventional glass slides can be problematic for both
methods as they emit fluorescent light when excited with visible
and near IR light, and absorb IR light at wavelengths of 3.5 µm
and longer, which constitute the fingerprint region for IR. Conse-
quently, both approaches often require special substrates - quartz
or CaF substrates for Raman studies, and CaF or BaF2 substrates
are used in IR. On the other hand, glass slides are transmissive to
IR wavelengths in the range λ= (2.8 to 3.5)µm, allowing only the
CH stretch spectral region to be used.144 Another consideration
is that the intrinsically low Raman scattering levels can be eas-
ily masked by fluorescence; thus, in addition to use of specialty
substrates, it is often necessary to photobleach samples before ac-
quiring Raman spectra.
The benefits of spectral image acquisition should be considered
in context of required imaging time. These considerations differ
significantly for IR and Raman spectral imaging. IR absorption
cross sections for fingerprint and CH stretch modes are typically
on the order of 10−18cm2, so most of the light will be absorbed for
a high density of absorber with (5 to 10) µm path length. Having
such a large effect on transmitted light, signal can be acquired
very quickly. Yeh et al.21 describe work wherein 128 X 128 pixel
wide field IR absorption images were acquired serially on a fixed
region of the tissue while the laser wavelength was scanned. In
total, 282 frames were acquired, yielding IR absorption images
over a 1128 cm−1 range in the fingerprint region, with an effec-
tive pixel rate of 1.6 MHz, and spectral acquisition rate of 3 kHz.
In cases where fewer spectral points are required, some imaging
speed increase can be obtained by using only several discrete fre-
quencies. For example, Tiwari et al.153 found that they could
reliably identify diseased cardiovascular tissue regions with on-
the-order of 10 discrete spectral points.
Allowing for imaging of ∼10 discrete contrast frequencies and
a 5 µm pixel size, tissue could be mapped at 0.5 cm2/min, simi-
lar to WSI instruments currently in use. Further, if the discrete
frequencies are exclusively in the CH stretch region, glass slides
could be used, and there would be minimal impact on the histol-
ogy work flow, as IR imaging can be performed on H&E stained
slides.144
In contrast to IR absorption, the Raman signal is quite small,
and imaging with this contrast mechanism is proportionally slow.
The differential scattering cross-section of Raman-scattered light
collected of over solid angle (Ω) is given by dσ/dΩ ∝ |∂α/∂Q|2,
and is on the order of 10−30cm2 sr−1 for most modes. Accordingly,
spectral acquisition rates typically range from 5 to 0.01 Hz.113,154
Using spontaneous Raman scattering, one cannot excite only se-
lected vibrational frequencies, so there is no benefit to discrete
spectral imaging as in IR. On the other hand, some increase in
acquisition speed can be achieved through spatial multiplexing.
Figure 3 c displays a spontaneous Raman image acquired at a
90 Hz effective spectral acquisition rate148 through line-focused
(rather than spot-focused) excitation light. Because practical de-
tector arrays are presently limited to 2 dimensions, and one of
those is devoted to spectral variations, spontaneous Raman sig-
nal is limited to 1 dimensional multiplexing such as line excita-
tion. Of course, spatially multiplexed signal generation requires
light sources with proportionally scaled power.
a
b c
Fig. 3 IR and Raman histopathology: (a) Infrared absorption spectra
contain sufficient information for classification of tissue, and provide
value through indicating regions of interest. 145 (b) A: H&E stained
section of lymph node germinal and mantle zone, and B: a sub-image
with contrast from Raman spectroscopy showing activated lymphocytes
in yellow. 91 (c) Spatially multiplexed Raman spectroscopy with 30 ms
effective spectral acquisition time using 500 mW of 532 nm light. The
cytochrome-c distribution is indicated in yellow. 148
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Given the much slower acquisition speeds for spontaneous Ra-
man scattering, it is difficult to find an obvious application in the
histopathology work flow. For example, pixel sizes of 27 µm and
a 90 Hz spectral acquisition rate achieved through spatial multi-
plexing would provide appropriate sample throughput, but with
such course resolution, one would give up significant benefit of
sub-cellular chemical detail otherwise available from Raman scat-
tering. Spontaneous Raman imaging could be useful in a guided
subsampling mode, where only regions of special interest were
imaged. On the other hand, even with spatial multiplexing and
90 Hz spectral acquisition, only 0.003% of the total tissue area
could be imaged at high resolution in the 2 minute time frame
required to obtain a 1 cm2 whole slide brightfield image.
At this point it is appropriate to consider that the 2 minute /
slide imaging time is the standard for single-contrast image for-
mation, whereas Raman spectral images could contain most or all
of the potentially desired contrasts in a single, label-free image.
Nonetheless, it seems clear that some trade-off between coverage
and resolution would be necessary if spontaneous Raman scat-
tering is used. The severity of such a trade-off could be reduced
by use of coherent Raman techniques, which provide equivalent
spectroscopic information with imaging throughput that is closer
to that of WSI.
4 Coherent Raman Imaging
a
b
Fig. 4 Jablonski diagrams for CARS and SRL.
4.1 Introduction and Mechanism
Coherent Raman scattering was first predicted in 1962155 and
first measured in 1964.156 In 1982, Duncan et al.157 first demon-
strated the coherent Raman scattering effect in a microscope, but
the cross-beam (phase-matching) optical arrangement they used
was challenging. In 1999 Zumbusch et al.19 demonstrated that
the CARS effect could be achieved with a simple, collinear beam
geometry. This discovery gave rise to the now burgeoning field
of coherent Raman imaging (CRI). Currently, the most prominent
bioimaging CRI methods are stimulated Raman scattering (SRS)
and coherent anti-Stokes Raman scattering (CARS). It is not our
purpose to review the CRI field in its entirety; excellent reviews
have been given recently.158–162 Instead, we focus on applica-
tions of CRI to histopathology, and associated technical aspects
that facilitate or hinder such applications.
We can gain insight into coherent Raman scattering by consid-
ering that an oscillating electric field of light induces a polariza-
tion in a substance that can be described as:
P(t) = Nα(t)E sin(ωt) (1)
where P is an induced polarization, N is the number of molecules
in the sample volume, α is the molecular polarizability, and E
is the electric field amplitude of the light. As with spontaneous
Raman scattering, the coherent Raman cross-section depends on
changes of α with position along the normal mode coordinate, Q.
We consider α in terms of its Taylor expansion about Q= 0.
α(t)≈ α0+∑
m
∑
n
1
n!
∂ nα
∂ nQm
∣∣∣∣
0
Qnm(t) (2)
where n is the expansion order and m indexes normal modes.
In coherent scattering, vibrational modes are driven by exter-
nal light fields. When the difference in energy between a pump
(p) and Stokes (S) field is equal to the energy difference (Ωv) be-
tween two adjacent quantum levels of the vibrational mode, i.e.,
when Ωm =∆ω =ωp−ωS, energy can be transferred to that vibra-
tional mode. While the primary fields, E(t) = E je−iω jt , (j=p,S),
ωp > ωS  Ωm, are at much too high a frequency to directly in-
duce significant molecular response, electrons are able to follow
the fields adiabatically. Through its nonlinearity, the electron re-
sponse will contain some amplitude at the difference frequency,
∆ω. This component of the response will in turn exert an oscilla-
tory force F(t) on the molecule:163
F(t) =
∂α
∂Qm
∣∣∣∣
0
[
EpE?Se
−i∆ωt + c.c.
]
(3)
which will drive motion along the coordinate Q that can be de-
scribed by:
d2Qm(t)
dt2
+2γ
dQm(t)
dt
+ΩmQm(t) =
F(t)
µ
(4)
where Ωm is the resonant frequency, µ is the reduced mass of the
vibrational mode (not to be confused with the absorption dipole
described previously), and γ is a damping constant. Q(t) is then
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given as:
Qm(t) =
1
µm
∂α
∂Qm
∣∣∣∣
0
EpE?Se
−iΩmt
Ω2m−∆ω2−2i∆ωγm
(5)
Substituting Eq.(5) and a first-order truncation of Eq.(2) into
Eq.(1), we obtain an expression for the polarizability of a given
mode in presence of a pump and Stokes field:
αm(∆ω) =
1
µm
(∂α/∂Qm)20EpE
?
S
Ω2m−∆ω2−2i∆ωγm
(6)
and the resonant susceptibility is given by the following sum over
normal modes:
χ(3)R (∆ω) =
N0
6ε0∑m
1
µm
(∂α/∂Qm)20
Ωm− (∆ω)−2i∆ωγm , (7)
where, by convention, N0 is the number density of molecular os-
cillators in a pure substance. We see that χ(3)R is complex and
dissipative, so will have an overall spectral phase that varies with
Ω. The imaginary component of χ(3)R has essentially identical
164
line shape to the spontaneous Raman response. Molecular sys-
tems have an additional, nonresonant, susceptibility, χ(3)NR , that
arises directly through nonlinearity in the electronic response to
the driving laser fields. The overall third order susceptibility is
then given by:
χ(3)(∆ω) = χ(3)NR(∆ω)+χ
(3)
R (∆ω) (8)
In all third order coherent Raman processes, a pump and a
Stokes field interact with a medium according to:
C(∆ω) = χ(3)(∆ω)
[
ES ?Ep
]
(∆ω) (9)
where Ep, ES are the frequency-domain pump, and Stokes fields,
respectively and ? is the cross-correlation operator.
4.2 Coherent Anti-Stokes Raman Scattering (CARS)
Coherent anti-Stokes Raman scattering is generated by interac-
tion of a probe field with the vibrational coherence generated
through the process described by Eq.(9), as represented by the
Jablonski diagram in Fig. 4 a, and by the following expression:
ICARS(ω) ∝
∣∣∣[{χ(3) [ES ?Ep]}∗Epr](ω)∣∣∣2 (10)
where Epr is the frequency-domain probe field, ‘∗’ is the convo-
lution operator. For pump, Stokes, and probe sources with cen-
ter frequencies of ωp, ωS, and ωpr, respectively, the output anti-
Stokes frequency ωas =ω =ωpr+ωp−ωS =ωpr+∆ω. In the limit
that the probe pulse is spectrally narrow, we can treat it as a delta
function, so the CARS signal contains the same spectral informa-
tion that is contained in the spontaneous Raman signal. However,
there are important differences between CARS and spontaneous
Raman scattering. One of these is that the CARS signal is blue-
shifted with respect to the excitation light, so does not compete
with autofluorescence from the sample. Also, the CARS signal is
forward-scattered, and contained in a narrow cone angle, making
it a simple matter to collect a large fraction of the CARS light in a
transmission geometry.
Another important difference is that CARS signal contains a
nonresonant background (NRB), arising from χ(3)NR . It is termed
"nonresonant" because it arises from the electronic response, and
is not sensitive to vibrational resonances. Since the electrons adi-
abatically follow the driving field of the laser, the NRB is always
in phase with the driving field, and retains a fixed phase relation-
ship with the resonant response. The overall CARS signal has a
component that is a coherent mixing between these two terms:
ICARS(ω) ∝
∣∣∣χ(3)NR(ω)∣∣∣2+ ∣∣∣χ(3)R (ω)∣∣∣2+2χ(3)NR(ω)Re[χ(3)R (ω)] (11)
Owing to the three terms in Eq. (11), the qualitative nature
of the raw CARS signal depends on the ratio of resonant to non-
resonant response. χ(3)NR is of similar magnitude for most biolog-
ical materials but χ(3)R may vary widely owing to the density of
molecular oscillators, N˜ (fraction of N0 within the focal volume)
and the Raman scattering cross-section of individual vibrational
modes. Typically, χ(3)NR ≤ 0.1N˜χ(3)R for CH stretch resonances and
ICARS ∝ N˜2. However, for many fingerprint peaks, χ
(3)
NR  N˜χ(3)R
and the resonant contribution to the ICARS is linear in N˜, but NRB
dominates the signal. This is why non-spectroscopic CARS is per-
formed almost exclusively with CH stretch resonances as contrast.
In fact, considering only the term |N˜χ(3)R |2, Cui et al.165 demon-
strated that the resonant CARS signal amplitude is greater than
spontaneous Raman only when oscillators are very concentrated,
such as in bulk phase, and samples rich in lipid or structural pro-
tein.
Another important effect of the coherent interaction between
resonant and non-resonant signal components arises from the
Gouy phase shift, wherein a phase shift accrues with field prop-
agation beginning at the focus of a Gaussian beam compared to
propagation of a plane wave. This becomes a problem at sharp
interfaces of features smaller than the Rayleigh range when res-
onant signal is generated only by light on one side of the focus
while the non-resonant signal is generated at positions on both
sides of the focus. When these mix, there is a spatial position-
dependent spectral phase error166 causing spectral distortion.
However, the Gouy phase is not a problem when χ(3)NR  N˜χ(3)R ,
or when there are no sharp spatial discontinuities in resonant sig-
nal contribution.167
4.2.1 CARS With CH-Stretch Contrast
In the CH-stretch spectral range there are four main peaks, lo-
cated at 2850 cm−1, 2880 cm−1, 2920 cm−1, and 2960 cm−1.
These correspond to symmetric and assymetric stretching of CH2
(νCH2,sym, νCH2,asym), and symmetric and assymetric stretching of
CH3 (νCH3,sym, νCH3,asym), respectively. Because proteins have pri-
marily CH3 moieties and lipids have many more CH2 groups,
these peaks are convenient for estimating the relative abundance
of protein and lipid. The information content in (symmetric,
asymmetric) peak pairs is largely redundant, so only one peak
from each pair is typically used. The water OH stretch has a broad
resonance between 3000 cm−1 and 3600 cm−1 that is also used in
some studies.
CARS imaging with contrast from the CH stretch region can
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be performed by narrowband,19 spectral focusing,168 and spec-
troscopic techniques.169–172 In narrowband CARS, a pair of pi-
cosecond pulses is used to excite coherence of a single selected
vibrational band, and the higher frequency field is used to probe
the coherence. Meyer et al.173 found that, for strong resonant sig-
nals (χ(3)R ≥ 10Nχ(3)NR), simple subtraction of NRB is sufficient to
render a quantitative signal with no significant distortions to the
CARS peak positions and amplitudes. Wu et al.174 have shown
quantitative correspondence between νCH2,sym signals and lipid
content in liver tissue. Further, large resonant signals in the CH-
stretch enables rapid image acquisition, with pixel rates as high
as 6 MHz,175 but more typically range form 200 kHz176 to 1
MHz173 for tissue samples. Repeated images can be acquired at
several discrete Raman shifts to map scenes with some chemi-
cal complexity. For for discriminating species that are spectrally
distinct, like water and a protein or a lipid, a single additional
scan is generally sufficient for each component.177 A larger num-
ber of spectral contrast points may be necessary to discriminate
species with only subtle differences.173 Given the high pixel ac-
quisition rates, the necessity of acquiring several scans may not
itself be onerous, but latency between scans for wavelength tun-
ing can add significant time to image acquisition for most CARS
systems. Rapid spectral scan approaches have been demonstrated
for narrowband CARS with only 100 µs required to scan from one
frequency to another in the CH stretch region, making inter-scan
latency a non-issue for such systems.178
Spectral focusing is another approach that facilitates spec-
troscopic scanning with narrowband CARS. In spectral focusing
CARS,168 a pair of pulses that are spectrally broad and centered
at distinct wavelengths are temporally broadened with nominally
identical chirp. Although the absolute frequencies of the two light
fields impinging on the sample changes significantly with time,
variation in the difference of frequencies is minimized so a single
vibrational state can be excited. Using this approach, it is feasible
to collect single-frequency image pixels at 250 kHz.179 This ap-
proach to CARS can be performed with sub-picosecond pulses and
spectral tuning over a limited range (typically 500 cm−1) can be
accomplished by simply changing the delay of one pulse relative
to the other. When spectral focusing or another CARS approach is
performed at a series of Raman shifts, the effects of the NRB can
be separated through spectral phase retrieval approaches.180,181
Spectroscopic CARS differs from narrowband or spectral fo-
cusing CARS in that a broad swath of spectrum is obtained
in each laser shot. Such an approach in the CH-stretch re-
gion has been demonstrated with picosecond / femtosecond
CARS169,171,172,182 and and with nonlinear interferometric vi-
brational imaging (NIVI).183 Histological studies focused on CH-
stretch using spectroscopic CARS have been performed primarily
with NIVI. From tissues, NIVI typically yields CH-stretch spectra
with a bandwidth of ≈ 250cm−1 at a 20 Hz spectral acquisition
rate (1 kHz effective rate for a single frequency assuming 5 cm−1
resolution). These are undistorted Raman spectra, linear in N.183
Several studies have evaluated the utility of CARS in the CH
stretch region for generating contrast equivalent to H&E stain.
Evans et al.184 compared CARS images to H&E stained images,
finding that CARS could provide similar image information when
νCH2,sym and νCH3,sym or νCH3,asym were used. Similar "pseudo
H&E" obtained through intravital CARS imaging185 enabled in-
spection of tumor environments and margins without staining,
and no obvious evidence of photodamage even after 300 frames.
Quantitative tissue morphology metrics can be obtained from
CARS contrast, similar to what is done with H&E-contrast images.
Meyer et al.186 compare CARS with Raman in brain, demonstrat-
ing ability to extract nucleus-to-cytoplasm ratio, cell density, nu-
cleus size and shape. They found, however, that since nuclei have
negative νCH2,sym contrast, nuclear density and shape metrics may
not be as reliable as H&E. On the other hand, the Wong group
have used primarily νCH2,sym CARS contrast and image segmen-
tation187–189 to determine nuclear size, cell volume, and cell-cell
distance and other metrics to classify cancer subtypes in lung and
breast tissue, producing encouraging results for differential diag-
nosis of cancer in these tissues. Uckermann et al.190 also com-
pared metrics from CARS and H&E, finding that CARS provided
additional relevant information via the signal amplitude.
In addition to conveying morphological information through
imitating H&E stain, CARS νCH2 and νCH3 contrast has been used
to study lipid metabolism in cancer,191 and to discriminate cell
type based on lipid content. Excess lipids were found as a po-
tential marker for circulating tumor cells,192 and Evans et al.184
found contrast in νCH2,sym to evince replacement of normal white
matter with lipid deficient astrocytic glioma tissue. Chowdary et
al.193 found spectral differences arising from variation in lipid to
protein ratio in a rat breast cancer model, and were able to use
SVD to automatically segment normal and diseased tissue regions
at a 99% confidence level. Similarly, Uckermann et al.190 also
found a νCH2,sym contrast gradient in the infiltrative zone around
glioblastoma, with rather distinct contrast levels in the normal
region. They also found that levels of νCH2,sym contrast could
be used to distinguish between glioblastoma, and metasticized
breast tumor in the brain. In a similar finding, Meyer et al.103
showed that CARS νCH2,sym contrast in the brain could highlight
metastatic tumor regions of lung origin as the metastases retain
a chemical profile similar to the originating tissue. Their finding
was supported by Raman and IR imaging.
While narrowband CARS contrast from νCH2 and νCH3 alone
is useful in many circumstances, it can also be combined syn-
ergistically with contrast from other methods. Yue et al. used
CARS signal from νCH3,sym to visualize mammary acini, pro-
viding guidance for acquisition of spontaneous Raman spectra.
From subsequent spectral analysis, they observe changes in spa-
tial distribution of lipids concomitant with a loss of basoapical
polarity in mammary acuinus, a transformation linked to early
stages of carcinogens.161 The Popp group have taken similar ap-
proaches.103,154,173,194 In comparing CARS to spontaneous Ra-
man imaging of colon sections, Krafft et al.195 found that CARS
images were consistent with expectations from spontaneous Ra-
man scattering in the same spatial sample regions, and that with
just a few CARS scans in the range 3000 to 1000 cm−1, there was
sufficient information to discriminate a couple of cell types and
identify regions of normal and diseased tissue. The CARS images
were acquired 106 times faster than spontaneous Raman (10 µs
vs 30 s / pixel). Subsequently, they have used additional CARS
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peaks, in conjunction with other contrast mechanisms to charac-
terize tissues. The same pulses that generate the CARS signal can
also give rise to second harmonic generation (SHG) in collagen
fibrils, and to two-photon excited fluorescence (TPEF) from in-
trinsic fluorophores such as NADPH, flavins, collagen, and elastin.
Meyer et al.103,173 used CARS contrast at multiple Raman shifts
along with intrinsic contrast from TPEF and SHG to detect white
matter, the granule layer, elastin, ordered collagen, and NAD(P)H
in brain, and elastic fibers, triglycerides, collagen, myelin, cellular
cytoplasm, and lipid droplets in perivascular tissue.
4.2.2 CARS With Fingerprint Contrast
As we have seen above, CH-stretch contrast is useful for mor-
phology and some species quantification. However, contrast from
fingerprint spectra can provide abundance information for many
more species of diagnostic value. Some examples are shown in
Table 2, including carotenoids, cholesterol esters, glycogen, col-
lagen, keratin and elastin. Additionally, fingerprint spectra can
positively identify cell phenotype.146,152
Because the fingerprint peaks are typically much weaker than
the nonresonant signal, it is not possible to obtain quantitative
spectral information by simply subtracting the NRB. Because typi-
cally χ(3)R  χ(3)NR for fingerprint resonances, the third (cross) term
in Eq. (11) dominates the resonant contribution to the CARS
signal, and the overall spectral phase must be retrieved in order
to extract a Raman spectrum. CARS phase retrieval is possible
with an approach based on maximum entropy methods180 or one
based on time-domain Kramers-Kronig.181 Both provide function-
ally equivalent results, but the computations for the Kramers-
Kronig approach require considerably less time.196 It has recently
been appreciated that the estimate of the NRB shape estimate re-
quired by both of these methods can have a profound impact on
extracted Raman peak amplitudes. Camp et al.197 showed that
symmetry relations between the NRB and resonant signal can be
used to unambiguously determine the NRB shape, and thus the
relative peak amplitudes of the retrieved Raman spectrum. In
this way, the NRB acts as an internal calibration for spectroscopic
CARS, and using this internal calibration, retrieved peak ratios
are absolute.
Spectral acquisition of CARS signal is required for recovery of
Raman fingerprint signals through phase retrieval, and also facil-
itates system noise removal via singular value decomposition.198
Spectrally focused CARS179 can be delay-scanned used to gener-
ate spectroscopic images that are amenable to phase retrieval199
Additionally, several inherently spectroscopic CARS microscopy
approaches have been developed, but most are too inefficient for
biological imaging. Here we will exclusively consider approaches
that have been used to generate images from cells and tissues.
The first of these was based on a combination of spectrally broad
but uncompressed Stokes pulses, and spectrally narrow probe
pulses.171,172 This approach generates broadband CARS spectra
with up to 3000 cm−1 bandwidth at ≈20 Hz spectral acquisition
rate (12 kHz single spectral element, assuming 5 cm−1 resolu-
tion), with strong CH stretch but quite weak fingerprint spec-
tra.200 The quality of fingerprint spectra was improved signifi-
cantly in one case by implementation of a narrow-bandwidth sub-
nanosecond probe,201 and in another by using a temporally com-
pressed Stokes source.202 In the latter work, a nearly transform-
limited broadband pulse acts as both pump and Stokes, exciting
vibrational coherence much more efficiently than separate pulses.
This approach yielded CARS spectra in both CH and fingerprint
regions with uniformly high SNR across the spectrum, and 280 Hz
spectral acquisition rate (corresponding to 170 kHz single spec-
tral element acquisition, assuming 5 cm−1 resolution).202
Perhaps because it has only recently become possible to acquire
high quality fingerprint spectra in an imaging modality, there is
very little work on histological samples using fingerprint CARS.
With relatively weak fingerprint signal, Pohling:203 was able to
use principal component analysis to discriminate between gray
and white matter, and identify layers of granule and Purkinje
cells in mouse brain tissue. Their structural assignments agreed
with those obtained from H&E staining. Also in murine brain
tissue, but with significantly better SNR in the fingerprint due
to impulsive coherence generation, Camp et al.202 were able to
identify many diagnostically important species and features di-
rectly from spectral peaks, without multivariate analysis tech-
niques. These included red blood cells through the 1548 cm−1
and 1565 cm−1 hemoglobin peaks (C-C stretch), as well as colla-
gen, elastin, and nucleotides through peaks listed in Table 2 for
each of these species. They were able to identify tumor margins,
as there were spectral differences between normal and invasive
glioblastoma image regions, such as at 785 cm−1 (nucleotide),
1004 cm−1 (phenylalanine ring breathing), and 2956 cm−1 (CH3
stretch). In both the Pohling and Camp work, a tumor-associated
reduction in νCH2 was observed, as in CARS studies that focused
on CH-stretch.
In the mouse glioblastoma work, Camp et al.202 obtained SHG
and TPEF signals simultaneously with fingerprint CARS spectra.
Although SHG and TPEF are typically used to identify collagen
and elastin103,204 the multi-peak spectral identification of these
two proteins did not agree particularly well with the SHG and
TFEP images. They noted that SHG and TPEF provide uncer-
tain chemical specificity, as other biologically relevant molecular
species (such as NADH) are also known to generate a TPEF re-
sponse, and collagen generates a SHG response only when it is
coiled in a triple helix.
4.3 Stimulated Raman Scattering (SRS)
In stimulated Raman scattering (SRS), energy transfers from a
higher frequency (pump) field to a lower frequency (Stokes) field
when the frequency differences between the fields is equal to that
of a vibrational resonance in the material being probed. This ef-
fect can be monitored as stimulate Raman loss (SRL) in the pump
field, or stimulated Raman gain (SRG) in the Stokes field. An
expression for SRL can be given as:
ISRL(ω) ∝
∣∣∣[{χ(3) [ES ?Ep]}∗ES](ω)+Ep(ω)∣∣∣2 (12)
The theoretically achievable signal-to-noise ratio for SRS is the
same as that of CARS,208 and a related value, the sensitivity limit,
seems to be similar for both approaches.202 One important dif-
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Fig. 5 a & b: 205 (a) Immunohistochemical stain for Sox-10 in mouse ear with haematoxylin counterstain, revealing melanocytes in red. (b) CARS
image of adjacent slice to (a), showing pigmented regions, consistent with positive staining in (a). c& d: 202 (c) Pseudocolour BCARS image of tumor
and normal brain tissue, with nuclei highlighted in blue, lipid content in red and red blood cells in green. (d) Raman spectra retrieved from (c), with
each spectrum taken from one pixel, and acquired in 3.5 ms. e & f 206 SRH image (e) is compared to a similar section of tumor imaged after
formalin-fixation, paraffin-embedding and H&E staining (f). Comparison was made using a lookup table to match SRH "staining" with H&E. g & h 207
(g) Spectroscopic SRS images of pancreas and liver (left and right respectively). (d) Independent component spectra retrieved from (g) with 99% data
reduction
ference between SRS and CARS is that the SRS signal contains
only the imaginary component of the complex coherent Raman
response. Thus, the nonresonant component that is problematic
for narrowband CARS is not detected, and one directly obtains
a signal proportional to the spontaneous Raman scattering cross
section. (See Eq.(6))
ISRL(ω) ∝ ℑ
{
χ(3)(ω)
}
IpIS (13)
For field strengths permissible in tissue microscopy, the relative
change in pump or Stokes intensity is on the order of 10−6 to 10−8,
even for the strong peaks in the CH stretch region. These small
signals cannot be spectrally separated from the intense excitation
light as in CARS, so must be discriminated by other means, such
as lock-in or balanced detection methods. Under favorable condi-
tions, pixel acquisition rates up to 7 MHz have been demonstrated
with contrast from Raman peaks in the CH stretch region.209
However, 30 - 40 kHz pixel rates are more common for single
spectral bands in tissue samples.206,210 Furthermore, even the
strongest fingerprint peaks, such as found at 1440 & 1660 cm−1
(CH2 deformation & C−C stretch) are challenging to use for im-
age contrast with SRS. Ozeki et al.211 were unable to directly use
the 1660 cm−1 peak for contrast, even when pixel dwell times
were 10× longer than necessary for good SNR in the CH-stretch
region.
While the NRB does not interfere with the SRS signal, other
background signals can. These include two photon absorption
(TPA), cross phase modulation and thermal lensing. Signals from
these sources can have amplitude comparable to or greater than
even the largest SRS signals. For example, in skin, the TPA signal
exceeds that of CH stretch SRS by almost 100-fold.205 Not sur-
prisingly, these background signals can easily mask weak contrast
from the fingerprint region, and careful measures may be taken to
suppress their effects and recover some of the stronger fingerprint
signals.212,213
Because the SRS signal must be extracted directly from the
laser field, lasers with very low residual intensity noise (RIN) are
preferred. These are typically bulk lasers. However, fiber lasers
have a number of qualities that make them desirable in a clinical
setting, including being robust to physical movement, vibration,
and temperature shifts, and requiring very little maintenance. A
low-noise fiber source has been developed specifically for SRS214
although even for this laser, it is necessary to use both balanced
detection and lock-in approaches to recover the SRS signal.
4.3.1 SRS With CH-Stretch Contrast
As with CARS, SRS imaging in the CH-stretch region has been
performed with several approaches, including dual narrow-
band pulses,215,216 spectral focusing,217 rapid spectral scan-
ning,211,218 and simultaneous multi-band imaging.219 The same
chemical information can be obtained with CARS and SRS in the
CH-stretch region. Accordingly, the types of histology studies with
SRS are quite similar to those of CARS.
Using only contrast from the νCH3,sym band and morphological
clues, Mittal et al.220 were able to identify cell membranes, nu-
clei, collagen and keratin in tissues containing squamous cell car-
cinoma. In that study, the authors found that SRS images from
this single band provided similar information to that found in
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H&E images.
Lu et al.221 compared images from H&E staining to those gen-
erated with SRS contrast from νCH2,sym and νCH3,sym. They found
that cell density counts from SRS and H&E images were indistin-
guishable. However, using the lipid/protein ratio from the SRS
signal, and confirming this with luxol fast blue staining for the
myelin sheath, they found that the two SRS bands provided a
better distinction between white and gray matter than could be
achieved with H&E staining. They were also able to identify red
blood cells and vessels through morphological features of images
with contrast at 2800 cm−1, in the nominally quiescent region.
The contrast there may have arisen from TPA of heme. They also
found that necrotic regions were characterized by lack of nuclei
and lower protein signal, and banded regions of high protein sig-
nal appeared to be collagen.
Ji et al.222 used SRS contrast for νCH2,symm and νCH3,symm in
fresh surgical brain tissues from 22 patients to create a classifier
based on cellularity, axnoal density, and protein to lipid ratios,
which provided tumor infiltration detection with 97.5% sensitiv-
ity and 98.5% specificity. They found that SRS images were supe-
rior to H&E images for detecting infiltrating glioma, and that SRS
microscopy could detect invasive tumor cells in peri-tumor brain
tissue that appears grossly normal.
Orringer et al.206 used νCH2,symm and νCH3,symm bands from SRS
to recapitulate image contrast from H&E, but on unprocessed tis-
sue, with an eye towards improving intrasurgical tissue sampling.
Pathologist diagnosis based on proximally located SRS and H&E
tissue samples from 30 patients was compared and found to agree
92% of the time. They also used computer algorithm-derived im-
age attributes (based on SRS contrast) to successfully distinguish
between diagnostic classes of tumors with 90% accuracy.
Cui et al.223 used SRS spectra in the region (2800 to 3000)
cm−1 and multivariate curve resolution to find a correlation be-
tween cholesterol ester content in intracellular lipid droplets and
Gleason scores of prostate tissue. Using a calibrated surrogate
mixture for cellular lipid content, they found that the ratio be-
tween a band assigned to cholesterol at 2870 cm−1 and the
νCH2,sym band was proportional to the fraction of total lipids due
to cholesterol ester.
While full spectral information in the CH-stretch region is
sometimes useful, a small number of peaks often provide suffi-
cient discrimination. Otsuka et al.207 examined tissues from a
tumor-graft mouse model using spectrally scanned SRS spectrally
scanned over the range (2800 to 3100) cm−1. They found that
through independent component analysis, they could reduce their
spectral data set by > 95%, and still obtain images in which nu-
cleus, zymogen granules, lipid droplets, and red blood cells could
be visualized, and irregular glandular cell alignments detected.
They found that images from the reduced spectral data was qual-
itatively equivalent to H&E stained images. Similarly, Egawa et
al.224 used SRS spectroscopy in the range (2800 to 3100) cm−1
to map spatially resolved keratinocyte differentiation, and dis-
tinguish these from Langerhans cells in the spinous layer of the
epidermis. The key differences were primarily morphological, as
both cell shape and nuclear prominence differ between the cell
types, so the important contrast came at νCH2,symm and νCH3,symm
bands.
In other studies, vibrational signal from SRS has been used in
concert with other nonlinear contrast mechanisms. Freudiger et
al.210 combined νCH2,sym and νCH3,sym bands with hemoglobin TPA
to derive contrast of roughly equal quality to H&E-stained sec-
tions, recapitulating major histologic features in tissue from sev-
eral brain regions. Galli et al.225 used νCH2 in conjunction with
TPEF of an extrinsic label, and SHG from structured collagen to
observe significant differences in nuclear area of normal and can-
cerous regions in human tumors and murine tumor models. Yue
et al.226 used SRS νCH2,sym contrast for morphological imaging
in liver and prostate tissue, and for guidance in identifying lipid
droplets (LDs). They then used spontaneous Raman spectroscopy
at LD positions to determine that the cholesterol ester content of
the LDs was correlated with the ratio of 702 and 1442 cm−1 peak
intensity ratios, and with the aggressiveness of the cancer.
4.3.2 SRS With Fingerprint Contrast
As with CARS, little histology CRI has been performed with con-
trast in the fingerprint region. Ozeki211 showed that, for typical
modulation schemes, it is difficult to acquire image contrast us-
ing fingerprint Raman peaks. In CARS, the problem of weak fin-
gerprint signal was overcome with a highly efficient signal gen-
eration mechanism.202 While no analogous enhanced-efficiency
signal generation approach has been found for SRS, modulation
schemes have been demonstrated which discriminate against par-
asitic background signals sufficiently that fingerprint peaks can
be observed. Berto et al.212 proposed a scheme that exploits
the even modulation symmetry of various background signals,
providing sufficient discrimination to acquire fingerprint spectra
from mouse skin at a 20 Hz spectral acquisition rate (720 Hz
spectral pixel). Zhang et al227 were able to image cell nuclei us-
ing SRS with contrast from DNA at 785 cm−1, at pixel acquisition
rates on the order of 10 kHz. Fu et al.213 demonstrated an SRS
modulation approach that appears to 3 - 4×more effective for re-
jecting background signals that vary slowly with excitation wave-
length than amplitude modulation. They used delay-modulated
spectral focusing achieve ≈ 10mmole/L sensitivity from 720 cm−1
peak of acetylcholine in neuronal tissue with at a 250 kHz pixel
acquisition rate.
Colon tissues from 9 patients were imaged by spectrally
scanned SRS in conjunction with SHG, THG, TPEF.228 They found
that an increase in protein (νCH3,sym and Amide I), and water
(3250 cm−1), and a decrease in lipid (νCH2,sym, 1445 cm
−1, 1745
cm−1) all correlated with presence of adenocarcinoma. They re-
ported similarity in TPEF of NADH and 1665 cm−1 contrast im-
ages, suggesting that increased protein could be due to increased
metabolic activity. They also suggested that increased water in
cancerous regions could be due to increased aquaporin protein
production.
5 A Future Role For Coherent Raman Imag-
ing in Histopathology
We expect that CRI methods for histopathology will be adopted
to the extent they meet specific needs, and fit well into the es-
tablished histology work flow, possibly streamlining it. As early
1–25 | 15
applications are explored, and as physicians become increasingly
comfortable with the technology, it is possible that more complex
and potentially disruptive adaptations of this technology may be
adopted. In this section, we briefly discuss classes of problems
that CRI can address, both in the near and longer terms.
5.1 Immediacy of Information
It is not uncommon to have 24 hour latency between tissue exci-
sion and histology analysis. While this is often acceptable, there
are other situations, such as sampling a suspected tumor, and
intra-operative margin evaluation, in which immediate charac-
terization is optimal or even required. In these cases, label-free
and in situ histology modalities are desirable.
Tissue involved in and surrounding a tumor is typically sam-
pled and analyzed by histology or for biomarkers at various time
points to guide therapy by establishing prognosis and following
disease progression. Accordingly, inappropriate tumor sampling
is thought to be a leading problem in both prognosis and evaluat-
ing treatment response.229
Tissue sampling by needle biopsy or exploratory surgery is of-
ten guided by palpitation, preparative imaging, or visual inspec-
tion, and is notoriously inefficient.229 Neoplasms may be difficult
to properly sample at early stages, and the ability to categorize tis-
sue as normal or neoplastic during the biopsy process would go a
long way towards ensuring high-quality samples for subsequent
analysis. Spontaneous Raman was demonstrated decades ago
as an potential guidance tool for needle biopsy,230 and progress
has been made toward clinical adaptation, but challenges remain
with regards to low signal levels, and typically, Raman needle
probes must be coupled with other detection modalities.97 Coher-
ent Raman methods could easily provide sufficient signal levels
for this application. Narrowband CRI approaches have been im-
plemented in fiber,231–233 so could be adapted to needle biopsy,
but are probably not suited for this application since disease de-
tection would be based strictly on spectra, and thus benefit greatly
from sensitivity to multiple peaks in the fingerprint spectral re-
gion. Current broadband spectroscopic CRI approaches based on
impulsive excitation or spectral focusing will be difficult to imple-
ment in a fiber delivery, but other approaches may be possible in
the future.
While narrowband CRI may not be appropriate for purely spec-
troscopic disease detection, in needle biopsy, it is effective in a
microscopy modality for in vivo detection and analysis of skin car-
cinomas, which are present in the optically accessible epidermis
layer of the skin.194,205,220,234 New approaches to signal detec-
tion may push the useful range of in vivo CRI to slightly deeper
tissues,235 and to detection of fingerprint signals.213
Another widely recognized clinical problem is the need for in-
traoperative analysis of tissue at a resection margin. Strong corre-
lations exist between presence of cancer cells in surgical margins
and recurrence rates of cancer,236,237 and incomplete margin re-
section is held as a major cause for recurrence of cancers that call
for tissue conservation, such as in brain and breast.
A hand-held probe is required for in situ margin analysis, and
appropriate equipment has already been described for narrow-
band CRI231–233 although, to our knowledge, clinical studies us-
ing these probes have not yet been published. Use of a hand-held
Raman probe for identification of tumor tissue in surgical margins
was clinically demonstrated for brain surgery by Jermyn et al.238
and proof of principle for breast was demonstrated Kong et al.239
As with Raman needle probes, tumor detection in these reports
was based on spectroscopy alone, thus suffering somewhat from
low signal and precluding imaging. This difficulty was avoided in
the breast application by using autofluorescence levels to identify
regions of interest, and those regions were imaged sparsely with
Raman. In the brain application, the surgeon visually selected
regions of interest.
Although CRI technology has not yet progressed to in situ mar-
gin analysis, it has been demonstrated as an effective tool for
characterizing freshly excised, unprocessed tissue.206 Typically,
margin tissue must be frozen and stained for imaging. This pro-
cess can add 20 minutes to a surgery each time a margin is to
be investigated. The label-free nature of CRI, and the ability
to image in a backscattering mode makes it possible to obtain
histology-quality images from surface regions of thick, unpro-
cessed tissue, significantly reducing the delay between tissue re-
moval and analysis.206
Another area in which speed of information availability would
be useful is in initial evaluation of histology slides. The majority
of tissue in most slides is normal, so a pathologist may spend a
significant portion of their time searching for potential diseased
regions. One particularly strong benefit of chemical imaging is
that it can provide clear indications of tissue type and regions
of normal and potentially abnormal tissue. This regional tissue
typing has already been demonstrated with IR on slides from
which high-resolution H&E images have been obtained, and the
two images overlaid.145 CRI methods can provide both the re-
gional tissue typing184,190,193 and the high-resolution H&E mimic
without the need for staining or imaging in multiple contrast
modes.184,185,206
5.2 Better Quantification of Morphological Parameters
A survey of pathologists by the National Collation on Health Care
and Best Doctors36 gave lack of sub-specialty expertise the most
often suspected reason for cancer misdiagnoses from histology.
In that study, physicians most frequently indicated that improved
pathology resources (i.e., innovations in histopathology) is the
thing most needed to improve diagnostic accuracy. One particular
approach to improving pathology resources, namely CAD, aims to
bridge the sub-specialty expertise gap.
An important example of how CAD can bridge this gap is
through providing basic quantification of image features. As
mentioned previously, non-specialist pathologists were found to
be much less precise in cell counts and classification than sub-
specialists,87 no doubt contributing significantly to overall diag-
nostic uncertainty. Many of the same factors contributing to non-
specialist variability, including the fact that cells are often overlaid
in H&E images, with no clear delineation between nuclei.87 are
also challenges to the families of morphological image analysis on
which CAD is based. Further, factors such as variability in staining
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protocols, and in image field illumination, and issues with non-
specific staining contribute to overall image variability, adversely
impacting reliability in thresholding and feature identification for
CAD. These, and related issues are expected to be significant bar-
riers to widespread adoption of CAD. In recognition of this, the
US Food and Drug Administration has issued guidelines for per-
formance of WHI instrumentation.57
CRI methods can ameliorate or resolve many of the repro-
ducibility and reliability issues in image formation. For exam-
ple, obtaining reliable cell counts will be easier because CRI has
intrinsically high axial resolution, making it feasible to resolve
stacked nuclei. Additionally, where imaged nuclei are spatially
close, there will be a nuclear and cellular membrane signal be-
tween them, strengthening the ability of CRI-based analysis to
arrive at accurate cell counts. Yang et al.189 have already demon-
strated 90% accuracy and reproducibility in automated cell count-
ing using coherent Raman imaging with only νCH2,sym, and thus
poor nuclear contrast.186 This is an important near-term oppor-
tunity for coherent Raman methods.
In addition to intrinsic z-sectioning, CRI can provide a large
number of contrasts through various vibrational bands. Since in-
creased image dimensionality generally leads to higher precision
segmentation and feature identification,88–90 one could expect
improved performance in these aspects with these multi-contrast
images. The Wong group have derived morphological parame-
ters familiar to pathologists, such as cell shape and density, from
CARS images and based on these were able to identify with 80 to
95 % accuracy breast tumor types.189
Although CRI requires little or no sample preparation, it seems
likely that most early implementations will include fixation and
paraffin embedding of samples, simply for consistency with pro-
tocols for staining. In fact, both of these steps have potential
to introduce variability in CRI signals. Paraffin has a strong CH
stretch signal, and fixing agents can liberate diagnostically im-
portant molecules, particularly lipids.240 For example, compared
to fresh frozen tissue, formalin-fixed brain showed modification
in νCH2,assym and νCH3,assym amplitudes from CARS, but not in
νCH2,sym. In the fingerprint, only choline groups of phospholipids
at 717 cm−1 dropped slightly after formalin fixing. However,
methanol or acetone fixation severely reduced all these peaks and
others.241
5.3 Increased Chemical Information
Morphological analysis of an image from a single stain such as
H&E is sufficient for diagnosis in most cases. However, difficult
cases often require multiple additional stains to provide needed
auxiliary information, but many of these desirable stains are rare
or unavailable,2 and it seems that this lack of access is a clini-
cally significant issue.36 CRI with good fingerprint contrast has
potential to make an important contribution by providing a con-
siderable range of contrasts.
Fingerprint CRI provides chemical specificity identical to that of
spontaneous Raman spectroscopy,202 and therefore seems likely
to be a potential substitute for most or all stains, and perhaps
many IHC agents. Raman spectra can be used to recapitulate
many image contrast agents used commonly in biology.242 Also,
as shown by the partial listing in Table 2, fingerprint Raman has
already been used to detect many diagnostic markers. With fin-
gerprint CRI, these will be available as label-free image contrasts.
An important added benefit of spectroscopic CARS is that it pro-
vides an internal reference based on NRB,197 so that spectro-
scopic CARS images can serve as quantitative, rather than qualita-
tive maps of markers. This level of quantification cannot generally
be achieved with stains, fluorescence, or even spontaneous Ra-
man. The quantitative imaging and absence of non-specific stain-
ing will greatly simplify image analysis and increase confidence in
image metrics and associated diagnostic decisions. A few specific
examples of potential important contributions are given below.
The number density of mitotic cells plays an important role
in diagnosis and grading of many cancer types,8 and is usu-
ally determined by IHC or cell morphology analysis. The best
morphologically-derived automated detection of mitoses achieve
F-scores (the geometric mean of precision and accuracy) between
75% and 80%.86 It seems likely that fingerprint CRI imaging
could yield significantly better results. By mapping the intranu-
clear distribution of DNA, RNA, and chromatin, Raman spectro-
scopic imaging can not only positively identify whether a cell is
mitotic, but which stage of mitosis it is in.147,150,151 The chemical
distribution information is essentially orthogonal to morphologi-
cal analysis, so can only serve to increase precision and accuracy
in determining mitosis counts.
Accurate characterization of pleomorphism (atypical cell
shape) is also important to proper diagnosis of many cancers.8
Pleomorphic cells of one type may be mistakenly identified as nor-
mal cells of a different type, and this was part of a 42% cell count
and classification disagreement among non-specialists found by
Fuchs et al.87 It is well established that Raman spectroscopy can
be used to positively identify cell type.146 Applying spectral cell
identification as an orthogonal metric will facilitate much better
recognition of pleomorphism.
Invasion of immune cells into a tumor site, and their state of
activation is an key factor in diagnosis of some cancers.8 As men-
tioned above, morphology-based cell identification can be diffi-
cult, and determination of immune cell activation is currently
done by assessing the presence of cell surface markers, typically
by IHC. For this important problem, fingerprint spectroscopic
imaging will not only allow immune cell identification, but also
whether they are activated.91,152
Identifying the tissue from which of CUP (cancer unknown
primary) metastases originate is useful for identifying appropri-
ate therapeutic strategies, but presently requires involved analy-
sis.243–245 Fingerprint spectroscopic CRI may be able to positively
identify metastatic tumor origins simply from chemical content of
the tumor cells. Even narrowband CRI studies were able to dis-
criminate primary (metastasized) cancer cells from cells belong-
ing to the target tissue simply on basis of contrast at νCH2,symm and
νCH3,symm.
103,190
In recent years it has become clear that genomic subclasses of
cancers can have distinct clinical outcomes,246 and thus require
varied interventions. While spectroscopic Raman imaging has not
been evaluated as a tool for identifying these subclasses, it seems
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reasonable that it may have power to do so in some cases. CRI
will not directly detection genome changes, but it is likely to de-
tect downstream consequences of those changes. For example,
cell phenotype146 and function91,146 can be discriminated using
Raman spectra. These spectral changes come not from DNA se-
quence or methylation modifications directly, but from the intra-
and extra-cellular changes in bimolecular profiles they induce.
Furthermore, microenvironment properties determined through
histology have recently been found to correlate with the genomic
cancer subtypes, and these microenvironment changes should be
detectable with CRI in most cases.247.
5.3.1 Speed & Information Trade-off
Single frequency CRI approaches can provide imaging nearly as
fast to WSI instrumentation. CARS approaches typically provide
tissue imaging at pixel rates of 200 kHz to 1 MHz,173,176 as little
as a factor of three slower than commercial WSI. SRS instruments
seem to run a bit more slowly, typically at ≈50 kHz.206,210 How-
ever, a recent SRS demonstration achieves fingerprint contrast at
250 kHz, between 10 and 60 times slower than WSI. Although
these speeds may still be too low for widespread use, they present
only a minimal imaging rate-related barrier to applying narrow-
band CRI to histopathology problems in a research mode. Ac-
cordingly, reports of narrowband histology studies are beginning
to appear. On the other hand, many of CRI’s potential contri-
butions to histopathology will require chemical information be-
yond that attainable from a single Raman peak. Based on current
technology, there will be a significant speed penalty for increased
chemical information.
Broadband CRI tissue imaging using CH stretch has been
demonstrated at 20 Hz for CARS170 and for 4 kHz for SRS207,224
over 300 cm−1. Fingerprint CARS spectro-microscopy has been
demonstrated at 300 Hz over 3000 cm−1 in tissue.202 Overall,
these range in speed from 105 to 103 times slower than WSI.
This difference may be difficult to surmount. Assuming the 0.5
cm2/s imaging speed is indeed an appropriate mark, it seems that
present spectral CRI methods are not good candidates, although
some newer spectroscopic CRI approaches may hold promise. a
spectral focusing approach has been demonstrated at 77 kHz for a
200 cm−1 bandwidth,235 although not yet in tissue, and a family
of approaches featuring ≈ 25 kHz spectroscopic CARS acquisition
has been demonstrated,248,249 but with laser pulses incompati-
ble with tissue imaging. Broadband SRS250,251 has been demon-
strated with potentially fast imaging, but seem to suffer from in-
sufficient modulation sensitivity.
Assuming that signal generation and collection efficiency of
current CRI instruments is nearly optimal, and there is no way
to intrinsically speed up image acquisition, there are at least two
non-exclusive options for applying spectroscopic CRI. One is to
use a faster imaging modality (such as narrowband CRI) to gen-
erate a guide image from which regions of interest can be de-
termined, and use spectroscopic CRI over ROIs covering a small
fraction of the specimen. The other approach would be to use
spatial multiplexing.
Provided sufficient excitation laser power, spatial multiplexing
approaches can yield speed increases proportional to the num-
ber of detection elements. For spectroscopically detected signal,
such as in spontaneous Raman scattering, 1-D (line) spatial mul-
tiplexing can realistically lead to 20× - 100× imaging speed in-
crease.148 This approach could also be used for spectroscopic
CARS. 2-D multiplexing has been demonstrated with narrowband
CARS252–256 though not in ways suited for clinical applications.
Spectroscopic approaches using single element detectors, such as
time-domain248 or spectrally scanned179 CARS could also be 2-
D multiplexed, so 104× speed increase is conceivable, provided
laser sources of sufficient pulse energy can be found to spread
light over a larger area and still obtain signal. SRS will be more
challenging to implement in spatially multiplexed modes since
it requires very high sensitivity to small amplitude modulations.
Lock-in and balanced detection are not commonly available in an
array format, although examples do exist. Slipchenko et al.257 in-
troduced an array of 32 LC circuits for simultaneously detecting
SRS signal in as many channels, and CMOS cameras can be used
in differential or lock-in mode, but these have yet to demonstrate
needed sensitivity.250,251
Finally, we note that, using spectroscopic CRI, information stor-
age could be an issue. Storing single contrast images from WSI
instruments is already a challenge. If all histology images were
acquired in full spectral mode, this would increase the data stor-
age load by 103 times. This does not seem tenable. It is conceiv-
able that, ultimately, only a small fraction of overall tissue surface
will be imaged spectroscopically. Also, it is possible that not all
spectral dimensions will be necessary in every case,153 and that
acceptable protocols for reduction of spectral information can be
found.
6 Conclusions
We expect that coherent Raman imaging is most likely to find
acceptance in the clinic as a drop-in replacement for current tech-
nologies as it is able to help resolve recognized problems related
to detection, diagnosis, and treatment of disease. Such problems
are likely to include fast and reliable intra-surgical margin evalua-
tion, either through direct analysis of the surgical site or through
rapid analysis of freshly excised tissue. Similarly, CRI’s ability
to provide label-free molecularly specific signal quickly may be
useful for in-situ detection of small tumors or neoplasms in ex-
ploratory surgery or needle biopsy.
Intra-surgical microscopic analysis of excised tissue has already
been demonstrated. In-situ use will likely require a hand-held
probe with fiber-delivered excitation light and signal collection.
Whether in-situ tissue analysis will be best done by narrow-band
coherent Raman imaging or by coherent Raman spectroscopic
analysis is unclear at this time.
Another significant opportunity for CRI is facilitating improve-
ments in histology-based diagnoses. The art of histopathology
emerged near the end of the 19th century in nearly its present
form. Significant new knowledge of disease mechanisms has im-
proved interpretation of histological features, but, apart from the
introduction of IHC in the 1940’s, histopathology tools in use to-
day are largely the same as they were in the early 20th century. Ef-
forts to modernize histopathology practice are making headway,
however, fully transforming it from a subjective art to a quan-
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titative and objective science remains a challenge. Most of these
challenges involve variability and contrast reliability in image for-
mation. It appears that many of these issues, could be largely
resolved with CRI. Furthermore, spectroscopic CRI may provide
a significantly enhanced contrast space that will open new op-
tions for quickly stratifying cancer and other diseases, leading to
a more "personalized" diagnosis.
While opportunities for CRI to improve clinical practice are
clear, important barriers remain for widespread adoption in his-
tology practice. An increase in imaging speed for narrow-band
CARS and a slightly larger increase for SRS would be helpful.
For spectroscopic CRI, substantial imaging speed increases will
be necessary if they are to be used to a significant extent in an
imaging mode. Fortunately, the CRI field is still vibrant with new
innovations for increased imaging speed and chemical selectiv-
ity and sensitivity. Much work remains to demonstrate the utility
and reliability of these methods to the medical community. Fi-
nally, potential regulatory issues must be considered and resolved
to the extent that they are found.
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